Eyegate Pharmaceuticals Inc.

4.24-0.0300-0.70%Vol 3.69K1Y Perf -26.06%
Apr 16th, 2021 09:43 DELAYED
BID4.20 ASK4.24
Open4.27 Previous Close4.27
Pre-Market- After-Market-
 - -%  - -
Target Price
12.83 
Analyst Rating
Strong Buy 1.00
Potential %
200.47 
Finscreener Ranking
★+     43.75
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
+     38.67
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★+     41.71
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap30.10M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
20.88 
Earnings Date
5th May 2021

Today's Price Range

4.204.27

52W Range

3.208.18

5 Year PE Ratio Range

-1.40-1.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.58%
1 Month
-24.16%
3 Months
-31.46%
6 Months
13.87%
1 Year
-26.06%
3 Years
-28.83%
5 Years
-91.53%
10 Years
-

TickerPriceChg.Chg.%
EYEG4.24-0.0300-0.70
AAPL133.91-0.5900-0.44
GOOG2 288.56-8.1000-0.35
MSFT258.28-1.2200-0.47
XOM57.180.20000.35
WFC42.900.66001.56
JNJ161.350.96000.60
FB305.79-2.0300-0.66
GE13.600.05000.37
JPM153.391.22000.80
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.00
0.04
0.05
-1 929.20
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
-
-19 898.20
-19 823.10
-14 695.80
-
RevenueValueIndustryS&P 500US Markets
12.06K
0.00
-74.33
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.40-0.52-30.00
Q03 2020-0.40-0.44-10.00
Q02 2020-0.43-0.3811.63
Q01 2020--0.43-
Q04 2019-0.81-0.766.17
Q03 2019-0.75-1.15-53.33
Q02 2019-0.75-0.6020.00
Q01 2019-0.750.15120.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.41-13.89Negative
6/2021 QR-0.42-23.53Negative
12/2021 FY-1.47-8.09Negative
12/2021 FY-1.36-3.82Negative
Next Report Date5th May 2021
Estimated EPS Next Report-0.41
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume3.69K
Shares Outstanding7.10M
Trades Count32
Dollar Volume421.37K
Avg. Volume76.79K
Avg. Weekly Volume9.64K
Avg. Monthly Volume17.70K
Avg. Quarterly Volume56.59K

Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) stock closed at 4.27 per share at the end of the most recent trading day (a 1.67% change compared to the prior day closing price) with a volume of 11.88K shares and market capitalization of 30.10M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Eyegate Pharmaceuticals Inc. CEO is Franz Obermayr.

The one-year performance of Eyegate Pharmaceuticals Inc. stock is -26.06%, while year-to-date (YTD) performance is -13.39%. EYEG stock has a five-year performance of -91.53%. Its 52-week range is between 3.2 and 8.18, which gives EYEG stock a 52-week price range ratio of 20.88%

Eyegate Pharmaceuticals Inc. currently has a PE ratio of -2.60, a price-to-book (PB) ratio of 4.76, a price-to-sale (PS) ratio of 2 566.29, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -61.85%, a ROC of -141.17% and a ROE of -113.89%. The company’s profit margin is -%, its EBITDA margin is -19 823.10%, and its revenue ttm is $12.06 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Eyegate Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Eyegate Pharmaceuticals Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Eyegate Pharmaceuticals Inc. is Strong Buy (1), with a target price of $12.83, which is +200.47% compared to the current price. The earnings rating for Eyegate Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eyegate Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eyegate Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.10, ATR14 : 0.49, CCI20 : -136.20, Chaikin Money Flow : -0.30, MACD : -0.55, Money Flow Index : 23.25, ROC : -13.39, RSI : 36.40, STOCH (14,3) : 6.25, STOCH RSI : 0.32, UO : 25.16, Williams %R : -93.75), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eyegate Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
0
0
Moderate Buy
0 (0.00 %)
0
0
Hold
0 (0.00 %)
0
0
Moderate Sell
0 (0.00 %)
0
0
Strong Sell
0 (0.00 %)
0
0
Summary RatingStrong Buy
1.00
--

Eyegate Pharmaceuticals Inc.

Eyegate Pharmaceuticals Inc is a US-based clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The company's lead product EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through a proprietary drug delivery system, the EyeGate II Delivery System. It mainly develops EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body.

CEO: Franz Obermayr

Telephone: +1 781 788-8869

Address: 271 Waverley Oaks Road, Waltham 02452, MA, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

62%38%

Bearish Bullish

60%40%

News

Stocktwits